Loading…
Loading…
what your latest thoughts there are? How much you expect some of these other governments to work with you around pricing?
is there something that they're waiting for in that initial experience with patients that's giving them pause for increasing their prescribing right now?
I just wonder if you could speak a little bit more about which subgroups you might be considering diving deeper into beyond maybe just being the eosinophil counts
how you're thinking about what the shape might be of a launch in Europe and your commitment to Europe and ex U.S. geographies
can you guys talk a little bit more about what the bar for the futility analysis is going to be?